Dr. Nancy A. Simonian M.D.

Syros Pharmaceuticals

Nancy is the founding CEO of Syros and has an established track record of value creation in biotechnology. Prior to Syros, she was chief medical officer at Millennium Pharmaceuticals, and previously vice president of Clinical Development at Biogen. Nancy has overseen the successful development of numerous medicines. Under Nancy’s leadership at Millennium, VELCADE became a mainstay of treatment for multiple myeloma. She also led development of Millennium’s clinical pipeline, including NINLARO for hematologic malignancies and ENTYVIO for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX and TYSABRI for multiple sclerosis. She started her career as an assistant professor at Harvard Medical School and neurology staff at Massachusetts General Hospital. She trained in neurology and internal medicine at Massachusetts General Hospital and holds a BS in biology from Princeton.

Year appointed: 2012